Soylemez Investment

Mehmet Ali Söylemez, Managing Director of SÖYLEMEZ INVESTMENT, exemplifies this spirit of innovation and dedication. His groundbreaking discovery of the utility of Procalcitonin as a biomarker in Diabetes Mellitus has the potential to transform how diabetes is diagnosed and treated. Through rigorous research and over 47 publications validating his findings, His significant contributions to medical science have earned him a nomination for the 2024 Harvard Medical School Warren Alpert Prize.